Shopping Cart
- Remove All
- Your shopping cart is currently empty
N,N'-Dinitrosopiperazine (1,4-Dinitrosopiperazine, DNP) is a known carcinogen associated with the development and metastasis of nasopharyngeal carcinoma. Its carcinogenic mechanism involves multiple signaling pathways, particularly exerting effects through the regulation of phosphorylation at the Ser568 site of the LYRIC protein. It can be used to induce esophageal cancer models.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | N,N'-Dinitrosopiperazine (1,4-Dinitrosopiperazine, DNP) is a known carcinogen associated with the development and metastasis of nasopharyngeal carcinoma. Its carcinogenic mechanism involves multiple signaling pathways, particularly exerting effects through the regulation of phosphorylation at the Ser568 site of the LYRIC protein. It can be used to induce esophageal cancer models. |
In vitro | N,N'-Dinitrosopiperazine (referred to herein as 0.) exhibits specific activity within chemical processes by engaging in reactions characteristic to its molecular structure. |
In vivo | N,N'-Dinitrosopiperazine (administered via tail vein injection; 40 mg/kg; 30 days) suppresses cell motility and invasion while promoting nasopharyngeal carcinoma (NPC) metastasis in vivo. Immunohistochemistry (IHC) reveals that phospho-LYRIC levels are elevated in the metastatic tumors of DNP-treated mice compared to untreated controls [1]. |
Synonyms | DNPZ, 1,4-Dinitrosopiperazine |
Molecular Weight | 144.13 |
Formula | C4H8N4O2 |
Cas No. | 140-79-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
Solubility Information | DMSO: 3 mg/mL (20.81 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.